TEVA Teva Pharmaceutical Industries Limited American Depositary Shares

11.6
+0.25  (+2%)
Previous Close 11.35
Open 11.39
52 Week Low 6.07
52 Week High 13.76
Market Cap $12,705,019,944
Shares 1,095,524,777
Float 1,092,467,456
Enterprise Value $37,405,848,615
Volume 3,884,399
Av. Daily Volume 11,206,346
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Fasinumab
Osteoarthritis pain of the hip or knee
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Fremanezumab
Fibromyalgia
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Fremanezumab
Post-Traumatic Headache
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
AUSTEDO (deutetrabenazine)
Dyskinetic cerebral palsy (DCP)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
AUSTEDO (deutetrabenazine)
Tourette Syndrome
Phase 2/3
Phase 2/3
Phase 2/3 trial did not meet primary endpoint - February 19, 2020.
Fasinumab
Lower back pain
Phase 3
Phase 3
Phase 3 ongoing
HERZUMA
Herceptin biosimilar
Approved
Approved
FDA approval announced December 14, 2018.
TRUXIMA
Rituxan (rituximab) biosimilar
Approved
Approved
FDA Approval announced November 28, 2018.
Fremanezumab
Migraine
Approved
Approved
FDA Approval announced September 14, 2018.
Fremanezumab
Cluster headache
Phase 3
Phase 3
Phase 3 trial to be terminated due to lack of efficacy - noted June 15, 2018.
Trisenox
Acute Promyelocytic Leukemia
Approved
Approved
Approved January 15, 2018.

Latest News

  1. Open-label extension of the FOCUS Phase IIIb study examined changes in quality of life, health status, depressive symptoms and work productivity over 12 weeks

    Pooled Phase 3 results examined changes in disability using American Headache Society guidelines

    Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced new data examining quality of life, health status, depressive symptoms, work productivity and activity impairment of patients treated with AJOVY during the 12-week open-label extension of the Phase IIIb FOCUS study. An additional analysis of pooled results from three AJOVY Phase III trials (FOCUS, HALO-Episodic Migraine, HALO-Chronic Migraine) examined headache- and…

    Open-label extension of the FOCUS Phase IIIb study examined changes in quality of life, health status, depressive symptoms and work productivity over 12 weeks

    Pooled Phase 3 results examined changes in disability using American Headache Society guidelines

    Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced new data examining quality of life, health status, depressive symptoms, work productivity and activity impairment of patients treated with AJOVY during the 12-week open-label extension of the Phase IIIb FOCUS study. An additional analysis of pooled results from three AJOVY Phase III trials (FOCUS, HALO-Episodic Migraine, HALO-Chronic Migraine) examined headache- and migraine-related disability based on guidelines set forth by the American Headache Society (AHS). The data were presented at the AHS Virtual Annual Scientific Meeting.

    "Migraine is more than just a headache and profoundly disrupts all aspects of life, including family life, social interactions and workplace success," said Denisa Hurtukova, MD, Vice President, Head of North America Medical Affairs. "It is critical that we take these aspects into consideration when developing a treatment plan and these new AJOVY data broaden our understanding of overall quality of life. Teva is committed to ongoing evaluations of AJOVY and supports clinically meaningful guidelines set forth by the AHS and other professional organizations."

    Quality of Life, Health Status, Depressive Symptoms and Work Productivity in the FOCUS Phase IIIb Open-Label Extension

    The FOCUS Phase IIIb open-label extension examined quality of life, health status, depressive symptoms and work productivity observed over an additional 12 weeks of treatment with AJOVY. FOCUS evaluated quarterly and monthly treatment with AJOVY compared to placebo in adult patients with migraine and documented inadequate response to 2-4 classes of prior preventive treatments. All patients completing double-blind treatment entered the 12-week open-label extension and received a monthly dose of AJOVY (225 mg) for three months (n=772).

    The following results were observed in quality of life, health status, depressive symptoms, and work productivity based on scores from validated patient-reported questionnaires, including Migraine-Specific Quality of Life (MSQOL), 5-level EuroQol-5 Dimension (EQ-5D-5L), Patient Global Impression of Change (PGIC), 9-item Patient Health Questionnaire (PHQ-9), and Work Productivity and Activity Impairment (WPAI) questionnaire:

    • MSQoL quality-of-life domain scores and the EQ-5D-5L health status score at the end of the double-blind period (change from baseline: MSQoL, 11.9 to 17.5 points; EQ-5D-5L, 4.7 to 7.2 points) and through the end of the open-label extension (change from baseline: MSQoL, 18.3 to 24.6 points; EQ-5D-5L, 7.3 to 8.0 points).
    • The proportion of patients who experienced a response on the PGIC (rating of moderate to a great deal better) increased from 58% to 64% at the end of the double-blind period to 75% to 77% at the end of the open-label extension.
    • Depressive symptom scores (based on the PHQ-9) were reduced by 1.6 to 2.4 points by the end of the open-label extension.
    • 14.5% to 20% reductions from baseline were reported in overall health-related work impairment by the end of the open-label extension.

    Additionally, the safety and tolerability of AJOVY during this open-label extension was evaluated, with the most common adverse events (AEs) being injection-site reactions, such as injection-site erythema (6%). The reports of AEs leading to discontinuation were <1% and 3% for serious AEs.

    Disability Severity According to the AHS Consensus

    The AHS Consensus Statement provides guidelines on determining response to CGRP pathway targeted treatments for migraine. As changes in migraine frequency may not adequately assess treatment benefit in all patients, these guidelines recommended specific improvements in disability scores on the MIDAS and HIT-6 that would be considered clinically meaningful and evidence of response to treatment. The disability in patients treated with AJOVY (HIT-6 n=1,958; MIDAS n=1,702) was evaluated using pooled data from the three double-blind Phase III trials.

    A post-hoc analysis of the pooled Phase III study data based on guidelines set forth by the Consensus Statement noted AJOVY patients experiencing severe disability due to migraine at baseline achieved the following disability score reductions:

    • For patients with a baseline MIDAS score of 11-20, the proportion of patients achieving a 5-point reduction from their baseline score was 71% (quarterly) and 70% (monthly) with AJOVY and 49% with placebo.
    • The proportion of patients with a baseline MIDAS score of >20 who achieved a ≥30% reduction in points was 69% (quarterly) and 79% (monthly) with AJOVY and 58% with placebo.
    • The proportion of patients achieving a 5-point reduction from baseline in HIT-6 scores was 53% (quarterly) and 55% (monthly) with AJOVY and 39% with placebo.

    The complete data sets and full presentations can be accessed through the AHS website.

    About AJOVY® (fremanezumab-vfrm) injection

    AJOVY is available as a 225 mg/1.5 mL single dose injection in a prefilled syringe with two dosing options – 225 mg monthly administered as one subcutaneous injection, or 675 mg every three months (quarterly), which is administered as three subcutaneous injections. AJOVY can be administered in office by a healthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment. The AJOVY autoinjector has been approved by the FDA and is available in the U.S. In addition to the U.S., the AJOVY autoinjector is currently available in Germany and should soon be available in other select European markets.

    U.S. Important Safety Information about AJOVY® (fremanezumab-vfrm) injection

    Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.

    Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

    Adverse Reactions: The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.

    Please click here for full U.S. Prescribing Information for AJOVY® (fremanezumab-vfrm) injection.

    About Teva

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people's lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding AJOVY® (fremanezumab-vfrm) Injection, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

    • our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions, competing glatiramer acetate products and orally-administered alternatives; the uncertainty of commercial success of AJOVY or AUSTEDO®; competition from companies with greater resources and capabilities; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; ability to develop and commercialize biopharmaceutical products; efforts of pharmaceutical companies to limit the use of generics, including through legislation and regulations and the effectiveness of our patents and other measures to protect our intellectual property rights;
    • our business and operations in general, including: duration, and geographic reach of the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; interruptions in our supply chain, including due to potential effects of the COVID-19 pandemic on our operations and business in geographic locations impacted by the pandemic and on the business operations of our customers and suppliers; adequacy of and our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; implementation of our restructuring plan announced in December 2017; challenges associated with conducting business globally, including adverse effects of the COVID-19 pandemic, political or economic instability, major hostilities or terrorism; our ability to attract, hire and retain highly skilled personnel; our ability to develop and commercialize additional pharmaceutical products; compliance with anti-corruption sanctions and trade control laws; manufacturing or quality control problems; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; our prospects and opportunities for growth if we sell assets and potential difficulties related to the operation of our new global enterprise resource planning (ERP) system;
    • compliance, regulatory and litigation matters, including: increased legal and regulatory action in connection with public concern over the abuse of opioid medications in the U.S. and our ability to reach a final resolution of the remaining opioid-related litigation; costs and delays resulting from the extensive governmental regulation to which we are subject or delays in governmental processing time including due to modified government operations due to the COVID-19 pandemic and effects on product and patent approvals; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into S&M practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
    • other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

    and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2020 and our Annual Report on Form 10-K for the year ended December 31, 2019, including in the sections captioned "Risk Factors" and "Forward Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

    View Full Article Hide Full Article
  2. Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced 24 abstracts featuring data on AJOVY® (fremanezumab-vfrm) injection will be presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting which began June 13. AJOVY, indicated for the preventive treatment of migraine in adults, is the only long-acting anti-CGRP subcutaneous injection with the option of dosing only four times per year.i*+

    The data presented at AHS will focus on disability, quality-of-life and work productivity during the 12-week open label extension of the FOCUS Phase IIIb clinical trial, which evaluated AJOVY in adult patients with migraine and documented inadequate response to 2-4…

    Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced 24 abstracts featuring data on AJOVY® (fremanezumab-vfrm) injection will be presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting which began June 13. AJOVY, indicated for the preventive treatment of migraine in adults, is the only long-acting anti-CGRP subcutaneous injection with the option of dosing only four times per year.i*+

    The data presented at AHS will focus on disability, quality-of-life and work productivity during the 12-week open label extension of the FOCUS Phase IIIb clinical trial, which evaluated AJOVY in adult patients with migraine and documented inadequate response to 2-4 classes of prior preventive treatments. Additional abstracts examine disability outcome measurements from pooled analyses of three AJOVY Phase III trials – FOCUS, HALO-Episodic Migraine, and HALO-Chronic Migraine.

    "Migraine is the second leading cause of years lived with disability and imposes physical, emotional, and societal burdens worldwide," said Denisa Hurtukova, MD, Vice President, Head of North America Medical Affairs. "We are committed to advancing the understanding of the AJOVY patient experience by continuing to examine patients with difficult-to-treat migraine."

    All presentations can be accessed through the AHS website.

    The full list of Teva abstracts being presented includes:

    FOCUS Study Including Open-Label Extension

    Disability, Quality of Life, Patient Satisfaction & Depression

    • Health-Related Quality of Life Outcomes With Fremanezumab in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medication: Open-label Extension of the FOCUS Phase 3b Study
    • Work Productivity and Activity Impairment Outcome With Fremanezumab in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Open-label Extension of the Phase 3b FOCUS Study
    • Patient Satisfaction With Fremanezumab During the Open-label Period of the Phase 3b FOCUS Study in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications
    • Effect of Fremanezumab on Depression Status in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications During the Open-label Period of the Phase 3b FOCUS Study
    • Impact of Fremanezumab on Headache-related Disability in Patients With Migraine Who Failed 2-4 Classes of Preventive Medication: Results of the Open–label Extension of the Phase 3b FOCUS Study
    • Impact of Fremanezumab on Migraine-specific Quality of Life in Patients With Medication Overuse and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes in the FOCUS Study

    Efficacy and Safety

    • Efficacy of Fremanezumab by Prior Number of Preventive Treatments With Inadequate Response in Patients With Episodic Migraine and Chronic Migraine: Results of the International, Multicenter Phase 3b FOCUS Study
    • Efficacy and Safety of Fremanezumab in Patients With Episodic and Chronic Migraine and Inadequate Response to 2-4 Classes of Preventive Medications: Results of the Open-label Period of the Phase 3b FOCUS Study
    • Clinically Meaningful Responses to Fremanezumab in Patients With Migraine Who Failed 2–4 Classes of Migraine Preventive Medication: Results of the Open–label Period of the Phase 3b FOCUS Study
    • Impact of Fremanezumab on Migraine-associated Symptoms in Patients With Migraine Who Failed 2-4 Classes of Preventive Medications: Results of the Open-label Period of the Phase 3b FOCUS Study

    Subgroup Analyses

    • Impact of Fremanezumab on Disability in Migraine Patients With Medication Overuse and Documented Inadequate Response to 2-4 Classes of Preventive Treatments: Subgroup Analysis of the FOCUS Study
    • Efficacy of Fremanezumab in Male Patients With Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Results of the Randomized, Placebo-controlled FOCUS Study

    Pooled Phase III Results

    • Impact of Fremanezumab on Disability Severity According to the AHS Consensus: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
    • Disability Severity Category Shift with Fremanezumab Treatment: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
    • Efficacy of Fremanezumab Treatment in Patients ≥60 Years of Age With Episodic or Chronic Migraine: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
    • Improvements in Headache-related Disability With Fremanezumab in Patients ≥60 Years of Age With Migraine: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
    • Improvements in Quality-of-Life, Productivity, and Satisfaction With Fremanezumab in Migraine Patients ≥60 Years of Age: Pooled Results of 3 Randomised, Double-blind, Placebo-controlled Phase 3 Studies
    • Pooled Analysis of Cardiovascular Safety With Fremanezumab Treatment in Patients With Migraine by Number of Cardiovascular or Cerebrovascular Risk Factors
    • Pooled Analysis of Tolerability With Fremanezumab Treatment in Patients With Episodic or Chronic Migraine and Cardiovascular Medication Use at Baseline
    • Pooled Analysis of Cardiovascular Safety With Fremanezumab Treatment in Patients With Migraine and Concomitant Triptan Use

    Migraine & Headache Disease State

    • Depression and Migraine – a Double Whammy on Patient-reported Health
    • Narrative Review of Risk Factors and the Burden of Medication Overuse Headache on Quality-of-life and Co-morbidities

    Real-World Perspectives

    • A Real-World Perspective of Patients With Episodic Migraine or Chronic Migraine Prescribed AJOVY in the United States

    Patient Characteristics

    • Treatment Patterns and Characteristics of Patients Prescribed AJOVY, Emgality, or Aimovig

    About AJOVY® (fremanezumab-vfrm) injection

    AJOVY is available as a 225 mg/1.5 mL single dose injection in a prefilled syringe with two dosing options – 225 mg monthly administered as one subcutaneous injection, or 675 mg every three months (quarterly), which is administered as three subcutaneous injections. AJOVY can be administered in office by a healthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment. The AJOVY autoinjector has been approved by the FDA and is available in the U.S. In addition to the U.S., the AJOVY autoinjector is currently available in Germany and should soon be available in other select European markets.

    U.S. Important Safety Information about AJOVY® (fremanezumab-vfrm) injection

    Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.

    Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

    Adverse Reactions: The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.

    Please click here for full U.S. Prescribing Information for AJOVY® (fremanezumab-vfrm) injection.

    About Teva

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people's lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding AJOVY® (fremanezumab-vfrm) Injection, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

    • our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions, competing glatiramer acetate products and orally-administered alternatives; the uncertainty of commercial success of AJOVY or AUSTEDO®; competition from companies with greater resources and capabilities; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; ability to develop and commercialize biopharmaceutical products; efforts of pharmaceutical companies to limit the use of generics, including through legislation and regulations and the effectiveness of our patents and other measures to protect our intellectual property rights;
    • our business and operations in general, including: duration, and geographic reach of the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; interruptions in our supply chain, including due to potential effects of the COVID-19 pandemic on our operations and business in geographic locations impacted by the pandemic and on the business operations of our customers and suppliers; adequacy of and our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; implementation of our restructuring plan announced in December 2017; challenges associated with conducting business globally, including adverse effects of the COVID-19 pandemic, political or economic instability, major hostilities or terrorism; our ability to attract, hire and retain highly skilled personnel; our ability to develop and commercialize additional pharmaceutical products; compliance with anti-corruption sanctions and trade control laws; manufacturing or quality control problems; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; our prospects and opportunities for growth if we sell assets and potential difficulties related to the operation of our new global enterprise resource planning (ERP) system;
    • compliance, regulatory and litigation matters, including: increased legal and regulatory action in connection with public concern over the abuse of opioid medications in the U.S. and our ability to reach a final resolution of the remaining opioid-related litigation; costs and delays resulting from the extensive governmental regulation to which we are subject or delays in governmental processing time including due to modified government operations due to the COVID-19 pandemic and effects on product and patent approvals; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into S&M practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
    • other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

    and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2020 and our Annual Report on Form 10-K for the year ended December 31, 2019, including in the sections captioned "Risk Factors" and "Forward Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.


    i AJOVY(fremanezumab-vfrm) injection Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc.

    * "Long-acting" defined as efficacy measured over a 12-week period following a 675 mg (225 mg x 3) SC dose.i

    + 225 mg monthly administered as one subcutaneous injection, or 675 mg every three months (quarterly), which is administered as three subcutaneous injections.

    View Full Article Hide Full Article
  3. PHILADELPHIA, June 09, 2020 (GLOBE NEWSWIRE) -- The Philadelphia Chapter of the National Investor Relations Institute (NIRI) announced that its members have elected the following individuals to serve on the Board of Directors for a twelve-month term beginning in June 2020:

    • President: Lisa M. Caperelli, Founder, CAP Strategies, LLC
    • Executive Vice President: Alex Whitelam, IRC, Senior Manager, Investor Relations, AMETEK, Inc. (NYSE:AME)
    • Vice President, Treasurer: Christiane Pelz, Vice President, Investor Relations, Five Below (NASDAQ:FIVE)
    • Vice President, Membership: Garrett Low, Managing Director, Nasdaq (NASDAQ:NDAQ)
    • Vice President, Communications & Technology: Rebecca Gardy, IRC, Vice President, Investor Relations, Campbell Soup Company (NYSE…

    PHILADELPHIA, June 09, 2020 (GLOBE NEWSWIRE) -- The Philadelphia Chapter of the National Investor Relations Institute (NIRI) announced that its members have elected the following individuals to serve on the Board of Directors for a twelve-month term beginning in June 2020:

    • President: Lisa M. Caperelli, Founder, CAP Strategies, LLC
    • Executive Vice President: Alex Whitelam, IRC, Senior Manager, Investor Relations, AMETEK, Inc. (NYSE:AME)
    • Vice President, Treasurer: Christiane Pelz, Vice President, Investor Relations, Five Below (NASDAQ:FIVE)
    • Vice President, Membership: Garrett Low, Managing Director, Nasdaq (NASDAQ:NDAQ)
    • Vice President, Communications & Technology: Rebecca Gardy, IRC, Vice President, Investor Relations, Campbell Soup Company (NYSE:CPB)
    • Vice President, Programs: Edward Barger, Senior Manager, Investor Relations, Teva Pharmaceuticals (NYSE:TEVA)
    • Vice President, Professional Development: Joe Hassett, Senior Vice President, Gregory Communications
    • Advocacy Ambassador: Mark Donohue, IRC, Vice President, Investor Relations, Clarivate Analytics (NYSE:CCC)
    • Board Advisory Committee & Immediate Past President: Donna St. Germain, Managing Director, Bengal Communications LLC 
    • Board Advisory Committee: Shawn Southard, IRC, Principal, 19 Squared IR

    "NIRI Philadelphia's goal is to advance the professional development of its members by discussing current trends and issues affecting the world of Investor Relations, promoting an exchange of ideas, and offering members networking opportunities," said NIRI Philadelphia Chapter President Lisa M. Caperelli. "I am excited to collaborate with these accomplished Investor Relations professionals who volunteer their time and energy to serve as members of the chapter's Board."

    About the NIRI Philadelphia Chapter

    NIRI Philadelphia, formed in 1971, is a professional association of more than 70 investor relations officers, communicators, consultants and providers serving organizations in the Greater Philadelphia area. NIRI Philadelphia includes members from a variety of industries and market cap sizes who are responsible for communications between their organizations, the investing public, and the financial community.



    About the National Investor Relations Institute (NIRI) 

    Founded in 1969, NIRI is the professional association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. NIRI is the largest professional investor relations association in the world with more than 3,000 members representing over 1,600 publicly held companies and $9 trillion in stock market capitalization.




    Contact: Lisa Caperelli, 215-206-1822,

    Primary Logo

    View Full Article Hide Full Article
  4. Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report, demonstrating the company's social impact and responsibility performance. The report includes 2020 goals for specific topics and clear alignment with the United Nations Sustainable Development Goals. For the first time, an external reviewer validated select report content.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005410/en/

    The report details Teva's 2019 efforts to lessen the burden of existing and emerging health concerns. The company's commitment to address such challenges is reflected in its response to COVID-19 in 2020, including…

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report, demonstrating the company's social impact and responsibility performance. The report includes 2020 goals for specific topics and clear alignment with the United Nations Sustainable Development Goals. For the first time, an external reviewer validated select report content.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005410/en/

    The report details Teva's 2019 efforts to lessen the burden of existing and emerging health concerns. The company's commitment to address such challenges is reflected in its response to COVID-19 in 2020, including its efforts to ensure continuity of medicine supply, prioritize the safety of its employees and work with governments and public health organizations to advance solutions.

    "For Teva, ESG means working to improve the health of our patients and communities and running an accountable business," said Kåre Schultz, President & CEO of Teva. "This report demonstrates our actions to increase access to quality medicines, support our employees, protect the environment and enhance compliance, while keeping patients at the heart of what we do."

    Committed to bringing more quality, affordable treatments to more people, Teva is improving health through its broad portfolio. The company received more than 1,000 approvals for generic medicines and 25 approvals for specialty medicines. Teva also donated $246 million worth of medicines to patients across the globe. With its partners, Teva implemented custom programs for caregivers in seven countries. The company also received awards for efforts to increase access to medicine and public health leadership in supporting patients with multiple chronic conditions.

    Teva recognizes its impact on the environment, working to reduce pollution and ensure efficient use of energy and natural resources across its facilities and supply chain. Teva reduced greenhouse gas emissions by 17% from 2017, total waste by 13% from 2018 and total energy consumption by 6% from 2018.

    The company prioritizes the safety and well-being of its employees and achieved its best-recorded internal workplace safety performance to date.

    As the world faces new health challenges, Teva remains committed to improving the health of the nearly 200 million patients it serves daily—and of communities around the world. Click here to learn more about Teva's 2019 ESG Progress Report. For more information about Teva's response to COVID-19, please see Teva's COVID-19 Updates and Resources.

    About Teva

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people's lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to impact and effectively execute on our social, economic, environment and governance related strategy and goals; our ability to successfully compete in the marketplace; consolidation of our customer base and commercial alliances among our customers; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; the effectiveness of our patents and other measures to protect our intellectual property rights; our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; our business and operations in general, including: duration, and geographic reach of the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; interruptions in our supply chain, including due to potential effects of the COVID-19 pandemic on our operations and business in geographic locations impacted by the pandemic and on the business operations of our customers and suppliers; adequacy of and our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; challenges associated with conducting business globally, including adverse effects of the COVID-19 pandemic, political or economic instability, major hostilities or terrorism; our ability to attract, hire and retain highly skilled personnel; our ability to develop and commercialize additional pharmaceutical products; compliance with anti-corruption sanctions and trade control laws; manufacturing or quality control problems; disruptions of information technology systems; breaches of our data security and privacy; compliance, regulatory and litigation matters, including our ability to reach a final resolution of the remaining opioid-related litigation; costs and delays resulting from the extensive governmental regulation to which we are subject or delays in governmental processing time including due to modified government operations due to the COVID-19 pandemic and effects on product and patent approvals; governmental investigations; potential liability for patent infringement; product liability claims; and other financial and economic risks including our exposure to currency fluctuations and restrictions; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent SEC filings, including in the sections captioned "Risk Factors" and "Forward Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

    View Full Article Hide Full Article
  5. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA, TASE: TEVA)) ("Teva"), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of the current COVID-19 pandemic, the format of its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting. Teva's 2020 Annual Meeting will be held on Tuesday, June 9, 2020 at 4:30 p.m., Israel time (9:30 a.m., New York time), as previously announced.

    Shareholders will not be able to physically attend the 2020 Annual Meeting.

    To participate in the virtual 2020 Annual Meeting, holders of Teva's American Depositary Shares ("ADSs") and ordinary shares should visit www.meetingcenter.io/218625112 and, when prompted, enter their…

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA, TASE: TEVA)) ("Teva"), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of the current COVID-19 pandemic, the format of its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting. Teva's 2020 Annual Meeting will be held on Tuesday, June 9, 2020 at 4:30 p.m., Israel time (9:30 a.m., New York time), as previously announced.

    Shareholders will not be able to physically attend the 2020 Annual Meeting.

    To participate in the virtual 2020 Annual Meeting, holders of Teva's American Depositary Shares ("ADSs") and ordinary shares should visit www.meetingcenter.io/218625112 and, when prompted, enter their control number (see below). The meeting password is TEVA2020.

    Holders of ADSs

    Holders of ADSs as of the close of business on April 30, 2020 (the "Record Date") will be able to participate in the virtual 2020 Annual Meeting and ask questions through the online meeting platform.

    Record holders of ADSs should enter the 15-digit control number on the proxy card or Notice of Internet Availability of Proxy Materials previously received.

    Beneficial holders of ADSs that are registered in the name of a broker, bank or other agent must register in advance to participate in the virtual 2020 Annual Meeting and ask questions through the online meeting platform. To register, beneficial holders of ADSs must submit proof of ownership reflecting the number of ADSs beneficially owned as of the Record Date, along with their name and email address, to Computershare at . Requests for registration must be labeled as "TEVA MEETING REQUEST" and must be received no later than Friday, June 5, 2020 at 9:30 a.m., New York time. Beneficial holders of ADSs will then receive a confirmation of registration with a 15-digit control number by email from Computershare.

    Holders of Teva's ADSs may not vote through the online meeting platform. To vote, holders of ADSs should follow the instructions set forth in Teva's Proxy Statement filed with the Securities and Exchange Commission on April 22, 2020.

    Holders of Ordinary Shares

    Holders of Teva's ordinary shares as of the Record Date will be able to participate in the virtual 2020 Annual Meeting, vote their shares and ask questions through the online meeting platform. If a holder of Teva's ordinary shares would like to appoint another person to act as his/her authorized proxy, such proxy must be submitted along with an email address to Teva at , must be labeled as "TEVA MEETING REQUEST" and must be received no later than June 5, 2020 at 4:30 p.m., Israel time.

    Record holders of ordinary shares must enter a control number to access the online meeting platform. The control number will consist of the holder's Israeli identification number or Israeli company registration number as it appears in Teva's share register.

    Holders of ordinary shares registered pursuant to Section 177(1) of the Israeli Companies Law, 5759-1999 whose shares are held through a nominee company ("Non-Registered Holders") must register in advance to participate in the virtual 2020 Annual Meeting, vote their shares and ask questions through the online meeting platform. To register, Non-Registered Holders must submit proof of ownership (including Israeli identification number or company registration number) reflecting the number of ordinary shares beneficially owned as of the Record Date, along with their name and email address, to Teva at . Requests for registration must be labeled as "TEVA MEETING REQUEST" and must be received no later than June 5, 2020 at 4:30 p.m., Israel time. Such Non-Registered Holders will then be able to use their Israeli identification number or company registration number as it appears on the proof of ownership provided to Teva as the control number to access the online platform. If a Non-Registered Holder would like to appoint another person to act as his/her authorized proxy, such proxy must be submitted to Teva along with the proof of ownership.

    Additional information for holders of ordinary shares and ADSs on how to participate

    • Access the meeting platform at www.meetingcenter.io/218625112 and enter the meeting password TEVA2020 and your 15-digit control number (for holders of ADSs) or Israeli identification number or company registration number (for holders of ordinary shares) beginning on Tuesday, June 9, 2020 at 4:15 p.m., Israel time.
    • To submit a question before or during the meeting, visit www.meetingcenter.io/218625112 with your control number and click on the messages icon to submit your question.
    • If you encounter any technical difficulties with the meeting platform on the date of the virtual 2020 Annual Meeting, technical support will be available during this time and will remain available until the virtual 2020 Annual Meeting has ended.
    • Whether or not you plan to attend Teva's virtual 2020 Annual Meeting, we urge you to vote and submit your proxy in advance by one of the methods described in the proxy materials for the 2020 Annual Meeting.

    About Teva

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people's lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at http://www.tevapharm.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to our business and operations in general, including uncertainty regarding the magnitude, duration, and geographic reach of the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the first quarter of 2020 and in our Annual Report on Form 10-K for the year ended December 31, 2019, including in the sections captioned "Risk Factors" and "Forward Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

    View Full Article Hide Full Article
View All Teva Pharmaceutical Industries Limited American Depositary Shares News